Evaluating immuno-modulatory phytoglycogen nanoparticles for enhanced production of newcastle disease virus

评估免疫调节植物糖原纳米颗粒增强新城疫病毒产量的作用

• 批准号: 522188-2017
• 负责人: Wootton, KSarah
• 金额: $ 1.82万
• 依托单位: University of Guelph
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=640222
• 关键词: Evaluating; immuno; modulatory; phytoglycogen; nanoparticles

Viruses engineered to express antigens to promote a protective immune response against a particular pathogen(vaccine), or to deliver a therapeutic gene (gene therapy) or to treat cancer (oncolytic virotherapy) are essentialtools used in the prevention and treatment of human and animal disease. However, a considerable impedimentto the production of viruses as vaccines or therapeutic agents is the cost of manufacturing. The goal of thisproject is to test whether Phytoglycogen nanoparticle (PhG) technology from Mirexus can be used as a cellculture additive to dramatically increase viral vaccine vector production. Mirexus is a leadingbio-nanomaterials company based in Ontario that produces phytoglycogen nanoparticles with valuableperformance characteristics that are currently leveraged across a wide variety of personal care applications.While traditionally PhG has been marketed to the cosmetic and food industries, Mirexus is rapidly developingPhG-based technologies for the biomedical and pharmaceutical industries. Preliminary results indicate that aproprietary modification of PhG (immune-modulating-PhG, IM-PhG) enhances in vitro virus production andthis effect is conserved between cell lines derived from fish to humans and both aquatic and mammalianviruses, including a 1000-fold enhancement of influenza virus production. To grow their business and expandtheir applications platform, Mirexus is seeking to investigate whether IM-PhG can be used as a cell cultureadditive to boost production of viral vaccines. Although Mirexus has the expertise to synthesize and modify thePhG, they do not have the infrastructure (e.g. BSL 2 laboratory, access to viruses) or the virology expertisenecessary to conduct these experiments. The purpose of this Engage grant is to facilitate collaboration betweenMirexus and an academic virology lab that can evaluate whether the above mentioned enhancing effect extendsto the production of Newcastle Disease Virus, an industrially important vaccine vector for animal health, inmammalian cells and embryonated eggs. As Mirexus is a Canadian company, expansion of its applicationsplatform should lead to increased demand for this patented technology and more high tech jobs for Canadians.

设计用于表达抗原以促进针对特定病原体（疫苗）的保护性免疫反应，或传递治疗基因（基因疗法）或治疗癌症（溶瘤病毒疗法）的病毒是预防和治疗人类和动物疾病的重要工具。然而，生产作为疫苗或治疗剂的病毒的一个相当大的障碍是制造成本。该项目的目标是测试 Mirexus 的植物糖原纳米颗粒 (PhG) 技术是否可以用作细胞培养添加剂，以显着提高病毒疫苗载体的产量。 Mirexus 是一家位于安大略省的领先生物纳米材料公司，生产具有宝贵性能特征的植物糖原纳米颗粒，目前广泛应用于各种个人护理应用。虽然传统上 PhG 已销售给化妆品和食品行业，但 Mirexus 正在快速开发用于生物医学和制药行业的基于 PhG 的技术。初步结果表明，PhG（免疫调节-PhG，IM-PhG）的适当修饰可增强体外病毒的产生，并且这种效应在源自鱼类、人类以及水生和哺乳动物病毒的细胞系之间是保守的，包括将流感病毒的产生增强1000倍。为了发展业务并扩展应用平台，Mirexus 正在寻求研究 IM-PhG 是否可以用作细胞培养添加剂来提高病毒疫苗的产量。尽管 Mirexus 拥有合成和修饰 PhG 的专业知识，但他们没有进行这些实验所需的基础设施（例如 BSL 2 实验室、病毒获取途径）或病毒学专业知识。这项 Engage 赠款的目的是促进 Mirexus 与学术病毒学实验室之间的合作，该实验室可以评估上述增强效果是否延伸到新城疫病毒的生产，新城疫病毒是一种用于动物健康、哺乳动物细胞和胚胎卵的工业上重要的疫苗载体。由于 Mirexus 是一家加拿大公司，其应用平台的扩展应该会导致对该专利技术的需求增加，并为加拿大人带来更多高科技就业机会。